Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.02.2024 | Case report

Mepolizumab

Aggressive and invalidating atopic dermatitis

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Sabbe M, et al. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report. Journal of Medical Case Reports 18 : 1-8, Jan 2024. Available from: URL: https://dx.doi.org/10.1186/s13256-023-04255-8 Sabbe M, et al. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report. Journal of Medical Case Reports 18 : 1-8, Jan 2024. Available from: URL: https://​dx.​doi.​org/​10.​1186/​s13256-023-04255-8
Metadaten
Titel
Mepolizumab
Aggressive and invalidating atopic dermatitis
Publikationsdatum
01.02.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53587-z

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Diazoxide

Case report

Paclitaxel

Case report

Multiple drugs

Case report

Multiple drugs

Case report

Lenvatinib